Abstract: Late-phase tech transfer is not about reinventing a process.

Abstract: This webinar highlights Catalent’s GPEx® Lightning platform and transient expression capabilities, demonstrating how sponsors can accelerate biologics development while reducing time to critical decision points.

Abstract: Late‑phase program transfers often arrive with years of thoughtful process characterization (PC), carefully defined control strategies, and a deep scientific rationale that sponsors are rightly committed to preserving.

Abstract: Catalent’s Rapid Antibody Gene‑to‑Drug Substance program provides an accelerated, end‑to‑end pathway to move traditional monoclonal antibody programs from gene construct to GMP drug substance in as little as eight months.

Catalent has expanded its industry‑leading GPEx® Lightning platform to include HEK cell line development, creating a new standard for speed, expression control, and product quality in human-cell–based manufacturing.

The cell line development technology platform revolutionizes the generation of complex biologics with unmatched speed, scalability, and flexibility.

Summary: Characterizing molecular stability early is critical to advancing biologics through development and into the clinic.

Catalent’s mammalian cell line engineering and biomanufacturing capabilities, utilizing single-use systems, provide the flexibility and scalability needed to support our customers' growth.

This webinar will bring together industry leaders to discuss innovative strategies and practical solutions for manufacturing protein-based modality therapies.

In this webinar learn how the GPEx® Lightning platform accelerates the high-titer production of next-generation multispecific antibodies and complex protein biologics